Whalesbook
Growth Driven by Price, Not Volume
India's pharmaceutical market has seen double-digit growth for five consecutive months, but this expansion comes from higher prices and new products, not more patients. This trend is most noticeable in cardiac, respiratory, and anti-diabetic drugs.
Anti-Diabetic Segment Surges on New Generics
Sales for anti-diabetic drugs alone topped ₹2,000 crore in April 2026, up from ₹1,795 crore a year earlier. This segment, along with anti-infectives, gastro-intestinal, and cardiac drugs, leads the market. Anti-diabetics showed the strongest sales growth at 16% in April, increasing their market share by 60 basis points. This growth is driven by new product launches after the semaglutide patent expired in March 2026. Nomura reports 13 companies launched generic semaglutide, making about ₹44 crore in April sales and projecting an annual market of ₹528 crore. Analysts expect volumes to rise as these generics gain traction, given the segment's early stage in India.
Generic Semaglutide Launches Shake Up Diabetes Market
The March 2026 semaglutide patent expiry has drastically changed the diabetes and weight-loss drug market in India. Over 25 generic brands launched within weeks. Torrent Pharma leads the generic field with an estimated 38% market share and ₹17 crore in April sales. Zydus, Lupin, Dr. Reddy's, Eris, and Alkem also gained market share. This competition has lowered prices, more than tripling the GLP-1 agonist market's turnover to ₹1,736 crore in April 2026 from ₹545 crore in April 2025. Even with this pressure, Eli Lilly's Mounjaro maintained strong sales, exceeding ₹1,000 crore annually and remaining the top brand. This shows strong demand, allowing brands to coexist despite new pricing.
Company Valuations and Market Pressures
Sun Pharma, India's largest drugmaker, reported 15% sales growth in April. Its P/E ratio stands at 40.31, above the Nifty Pharma index average of 35.7, supported by its diverse portfolio and steady earnings. Analysts rate Sun Pharma a 'Buy' with a potential 6.40% upside. Eli Lilly's P/E ratio is around 33.69, similar to Sun Pharma's growth stock valuation. Torrent Pharma and Corona Remedies show even higher P/E ratios, reflecting high growth expectations. The Indian pharma industry faces a mixed situation. Despite positive overall growth, reliance on pricing power is evident due to slow volume increases. Nomura reported that in March 2026, pricing added 5.5% to growth, new products 3.5%, and volumes only 1.1%. Rising input costs, including energy, add pressure and could lead to more price hikes.
Concerns Over Growth Sustainability
However, the market's reliance on price increases and generic competition, rather than expanded patient access, raises concerns about sustainability. Rising input costs for energy and petrochemicals are already pressuring margins. Although essential medicines received a small price increase allowance in April 2026, it may not cover overall cost escalations. The rapid entry of generic semaglutide, while improving affordability, intensifies price competition and reduces margins for all companies. Patent expirations historically lead to significant price drops and rapid generic market share gains, a trend expected to continue. Companies with fewer products or pipelines heavily reliant on single blockbuster drugs face greater revenue risks. Additionally, India's significant reliance on imported Active Pharmaceutical Ingredients (APIs), especially from China (over 74% of imports), creates vulnerability to supply chain issues and price fluctuations.
What Lies Ahead for Indian Pharma
The market is set to keep evolving, especially in weight-loss drugs, with a focus on oral medications alongside injectables. Nomura views companies with strong pipelines and unique portfolios positively, maintaining a 'Buy' rating for Sun Pharma due to its scale and diversification. Analyst consensus also supports a 'Buy' for Sun Pharma, expecting moderate upside. Eli Lilly's continued investment in manufacturing shows confidence in future volume growth, particularly in obesity treatments, despite pricing pressures. The shift towards generics and price-sensitive markets means companies need ongoing innovation and cost efficiency for continued profits.